Cold agglutinin syndrome associated with infectious mononucleosis: A case report
DOI:
https://doi.org/10.5281/Keywords:
Infectious Mononucleosis, Virus Infections, Disease Epstein-Barr, Cold AgglutininAbstract
Background: Cold agglutinin syndrome (CAS) is a hemolytic anemia mediated by antibodies, mainly IgM, whose maximum activity occurs at 4 °C. It happens secondary to infectious, autoimmune or neoplastic diseases, due to the formation of antibodies that cross-react against erythrocyte antigens, particularly of the I system. Here, we describe a case of CAS associated to Epstein-Barr virus (EBV) reactivation in a patient with primary human immunodeficiency virus (HIV) infection.
Clinical case: 22-year old man with no medical history, hospitalized due to mononucleosis and anemic syndrome. Hemoglobin of 3.7 g/dL and elevation of lactate dehydrogenase were documented. In the peripheral blood smear it was observed spherocytosis, polychromasia and nucleated erythrocytes. EBV infection was confirmed with serology and viral load, as well as seronegative HIV infection with positive viral load. The C3d monospecific direct antiglobulin test was positive and an irregular antibody screening revealed the presence of an anti-I antibody. The patient received transfusion support and conservative treatment, with remission of the symptoms 2 weeks after admission.
Conclusions: Cold agglutinin syndrome is a rare, potentially fatal complication of infectious mononucleosis, which should be considered in the face of findings suggestive of hemolysis in order to initiate support measures in a timely manner.
Downloads
References
Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi: 10.1016/j.blre.2019.100648.
Gertz MA. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am. 2022;36(2):341-52. doi: 10.1016/j.hoc.2021.11.001.
Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:946. doi: 10.3389/fimmu.2020.00946.
Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019;3(12):1897-906. doi: 10.1182/bloodadvances.2019000036.
Thakral B, Bueso-Ramos CE. Unexpected presentation of cold agglutinin syndrome with B-acute lymphoblastic leukemia. Blood. 2022;139(26):3778. doi: 10.1182/blood.2022016015.
Jacobs JW, Gisriel SD. Cold agglutinin syndrome in a patient with anaemia and beta-thalassemia trait. Transfus Med. 2022;32(3):263-4. doi: 10.1111/tme.12864.
Dematapitiya C, Perera C, Chinthaka W, et al. Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker. BMC Infect Dis. 2019;19(1):68. doi: 10.1186/s12879-019-3722-z.
Teijido J, Tillotson K, Liu JM. A Rare Presentation of Epstein-Barr Virus Infection. J Emerg Med. 2020;58(2):e71-3. doi: 10.1016/j.jemermed.2019.11.043.
Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:590. doi: 10.3389/fimmu.2020.00590.
Klutts JS, Ford BA, Perez NR, et al. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol. 2009;47(10):3204-10. doi: 10.1128/JCM.00164-09.
Páez-Guillán EM, Campos-Franco J, Alende R, et al. Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis. Lipids Health Dis. 2021;20(1):177. doi: 10.1186/s12944-021-01603-9.
Jouini H, Chouaieb S, Boussetta K, et al. Hemophagocytic lymphohistiocytosis associated with an IgG Cold agglutinin. Transfus Clin Biol. 2019;26(4):324-8. doi: 10.1016/j.tracli.2018.08.159.
Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016(1):226-31. doi: 10.1182/asheducation-2016.1.226.
Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385(15):1407-19. doi: 10.1056/NEJMra2033982.
Scheckel CJ, Go RS. Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis. Hematol Oncol Clin North Am. 2022;36(2):315-24. doi: 10.1016/j.hoc.2021.12.001.
Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137(10):1295-303. doi: 10.1182/blood.2019003809.
Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320-30. doi: 10.1111/bjh.15109.
Despotovic J, Olmsted T. Cold AIHA and the best treatment strategies. Hematology Am Soc Hematol Educ Program. 2022(1):90-5. doi: 10.1182/hematology.2022000369.
Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017;129(22):2971-9. doi: 10.1182/blood-2016-11-693689.
Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72(10):651-8. doi: 10.1136/jclinpath-2019-205822.
Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140(9):980-91. doi:10.1182/blood.2021014955.
Gelbenegger G, Jäger U, Fillitz M, et al. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease. Blood Adv. 2023;7(10):1987-90. doi: 10.1182/bloodadvances.2022008574.
Berentsen S, Barcellini W, D'Sa S, et al. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?. Immunotherapy. 2022;14(15):1191-204. doi: 10.2217/imt-2022-0085.
Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021;138(20):2002-2005. doi: 10.1182/blood.2021012039.
Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132(5):547-550. doi: 10.1182/blood-2018-03-835413.
Tesfaye A, Broome C. A Novel Approach for Treatment of Cold Agglutinin Syndrome-Related Severe Hemolysis. Journal of Hematology. 2016;5(1):30-3.
De Boer ECW, Jalink M, Delvasto-Nuñez L, et al. C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia. Blood Adv. 2023 Jul 11;7(13):3128-3139. doi: 10.1182/bloodadvances.2022009402.
Lodi G, Resca D, Reverberi R. Fatal cold agglutinin-induced haemolytic anaemia: a case report. J Med Case Rep. 2010;4:252. doi: 10.1186/1752-1947-4-252.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Revista Médica del Instituto Mexicano del Seguro Social
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
